

- Gilles de la Tourette's syndrome and chromosome 22q11 deletion syndrome: clue to the genetics of Gilles de la Tourette's syndrome? *J Psychosom Res* 2006;61:365–368.
11. Fontenelle LF, Mendlowicz MV, Bezerra de Menezes G, dos Santos Martins RR, Versiani M. Asperger syndrome, obsessive-compulsive disorder, and major depression in a patient with 45,X/46,XY mosaicism. *Psychopathology* 2004;37:105–109.
  12. Tentler D, Johannesson T, Johannsson M, et al. A candidate region for Asperger syndrome defined by two 17p breakpoints. *Eur J Hum Genet* 2003;11:189–195.
  13. Annerén G, Dahl N, Uddenfeldt U, Janols LO. Asperger syndrome in a boy with a balanced de novo translocation:t(17;19)(p13.3;p11). *Am J Med Genet* 1995;56:330–331.
  14. Saliba JR, Griffiths M. Brief report: autism of the Asperger type associated with an autosomal fragile site. *J Autism Dev Disord* 1990;20:569–575.
  15. Herman GE, Henninger N, Ratliff-Schaub K, Pastore M, Fitzgerald S, McBride KL. Genetic testing in autism: how much is enough? *Genet Med* 2007;9:268–274.
  16. Wassink TH, Losh M, Piven J, et al. Systematic screening for subtelomeric anomalies in a clinical sample of autism. *J Autism Dev Disord* 2007;37:703–708.
  17. Steiner CE, Guerreiro MM, Marques-de-Faria AP, Lopes-Cendes I. Laboratorial diagnosis of fragile-X syndrome: experience in a sample of individuals with pervasive developmental disorders. *Arq Neuropsiquiatr* 2005;63:564–570.
  18. Gillberg C, Cederlund M. Asperger syndrome: familial and pre- and perinatal factors. *J Autism Dev Disord* 2005;35:159–166.
  19. Estéio M, Fett-Conte AC, Varella-Garcia M, Fridman C, Silva AE. Molecular and cytogenetic analyses on Brazilian youths with pervasive developmental disorders. *J Autism Dev Disord* 2002;32:35–41.
  20. Meyer GA, Blum NJ, Hitchcock W, Fortina P. Absence of the fragile X CGG trinucleotide repeat expansion in girls diagnosed with a pervasive developmental disorder. *J Pediatr* 1998;133:363–365.
  21. Gillberg C, Wahlström J. Chromosome abnormalities in infantile autism and other childhood psychoses: a population study of 66 cases. *Dev Med Child Neurol* 1985;27:293–304.
  22. Gillberg C, Steffenburg S, Jakobsson G. Neurobiological findings in 20 relatively gifted children with Kanner-type autism or Asperger syndrome. *Dev Med Child Neurol* 1987;29:641–649.
  23. Gillberg C. Asperger syndrome in 23 Swedish children. *Dev Med Child Neurol* 1989;31:520–531.
  24. The Autism Chromosome Rearrangement Database. Available at: <http://projects.tcag.ca/autism/>. Accessed August 1, 2008.
  25. Akefeldt A, Gillberg C. Hypomelanosis of Ito in three cases with autism and autistic-like conditions. *Dev Med Child Neurol* 1991;33:737–743.
  26. Taibjee SM, Bennett DC, Moss C. Abnormal pigmentation in hypomelanosis of Ito and pigmentary mosaicism: the role of pigmentary genes. *Br J Dermatol* 2004;151:269–282.
  27. Farzin F, Perry H, Hessel D, et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. *J Dev Behav Pediatr* 2006;27:S137–S144.
  28. Kopra K, von Wendt L, Nieminen-von Wendt T, Paavonen EJ. Comparison of diagnostic methods for Asperger syndrome. *J Autism Dev Disord* 2008;38:1567–1573.

## Response to letter by Chodirker and Chudley

### To the Editor:

We have read the letter to the editor by Drs. Chodirker & Chudley entitled “Routine Genetic Testing for Asperger Syndrome” with great interest. We thank them for their thoughtful comments and recommendations given toward a complex issue. We also appreciate the opportunity to respond to their letter.

Our initial response is, in general, agreement with the basic premise put forth. That is, there is a paucity of published studies that have specifically looked at a diagnostic yield when Asperger syndrome is selected out from the rest of the Autism Spectrum Disorders.

Given the absence of such reports, Drs. Chodirker and Chudley reviewed the literature in search of documentation of genetic testing abnormalities and persons with Asperger syndrome. What they found was a handful of cases of patients with Asperger syndrome and abnormal genetic tests. Given the small number of cases that could be extracted from the litera-

ture, it is not possible to approach a statistical estimate with certainty. It is interesting to note from their table that they ultimately found 147 patients with Asperger syndrome in the existing reports, with 13 (9%) positive tests. It is notable that this is still in the reported range of positive studies from individual reports.

One point that we would raise as different from their interpretation is in the dismissal of several positive tests as “unlikely” to be etiologically causative or “comorbid.” We suggest that the identification of the six chromosome anomalies should be considered as possibly/probably related. In particular, the association of 22q11 deletions and autisms is well-enough documented that in our opinion, it should not be dismissed.

Another point of note is that all existing studies share some sort of selection bias, by nature of the clinical source of patients ascertained. Such bias has often been cited as leading to an overestimate of the diagnostic yield. Still, recent studies that have not found Fragile X in their patients have suggested that preselection (either intentional or not) may remove patients with Fragile X and lead to an underestimate.<sup>1,2</sup>

Finally, the foundation for what are made as recommendations based on an existing (albeit incomplete) body of literature comes down to the proverbial “lumper” versus “splitter” bias of the genetics provider making the recommendations. In the latter’s mind, one should not make a recommendation for genetic testing in Asperger syndrome until there are specific studies that have addressed that particular issue. Alternatively, a synthesis of the literature coupled with an understanding of what a spectrum means could lead one to recommend studies for all those who fall into the spectrum until there is evidence to the contrary. With the goal of providing a unifying diagnosis for as many patients as possible, we fall into this category.

**G. Bradley Schaefer, MD**

University of Arkansas for Medical Sciences  
Arkansas Children’s Hospital  
Little Rock, Arkansas

**Nancy J. Mendelsohn, MD**

Division of Medical Genetics  
Children’s Hospitals & Clinics of Minnesota  
Minneapolis, Minnesota

### References

1. Abdul-Rahman OA, Hudgins L. The diagnostic utility of a genetics evaluation in children with pervasive developmental disorders. *Genet Med* 2006;8:50–54.
2. Herman G. Genetic evaluation of the child with isolated autism. Proceedings of the Annual Meeting of the American College of Medical Genetics 2008:Abstract #313.

## Clinical significance of tri-nucleotide repeats in Fragile X testing: A clarification of American College of Medical Genetics guidelines

### To the Editor:

The purpose of this letter is to reconcile a discrepancy between two documents issued by the American College of Medical Genetics: the Technical Standards and Guidelines for Frag-

ile X testing published in 2001<sup>1</sup> and updated in 2005<sup>2</sup> and the Genetics Practice Guidelines statement on diagnostic and carrier testing for Fragile X syndrome published in 2005.<sup>3</sup> In the Practice Guidelines, a broad range of 41–60 trinucleotide repeats was described for the intermediate or “gray zone” in Fragile X syndrome based on a research context. That is, research groups used this broader range to identify high-risk alleles. More relevant to the clinical setting, a range of 45–54 trinucleotide repeats was quoted for the gray zone in the Technical Standards and Guidelines publication. For a summary of these ranges please see Table 1.

Differences in the intermediate range then led to discrepancies in the reported ranges for Fragile X premutations. In the Practice Guidelines, the premutation range is characterized as 61–200 repeats, whereas in the Technical Standards and Guidelines, the premutation range is defined as 55–200 repeats. The American College of Obstetricians and Gynecologists based their committee opinion on the ACMG Practice Guidelines, leading to confusion among physicians in interpretation of Fragile X test reports. The ranges for intermediate and premutation Fragile X alleles quoted in the 2005 Practice Guidelines have never been used in laboratory practice. After an extensive review of the literature in 2005, the Quality Assurance Committee of the ACMG determined that no changes were required to the ranges originally published in 2001.

In a recent article summarizing two multidisciplinary workshops focused on reproductive counseling for FMR1 premutation carriers, Wittenberger et al.<sup>5</sup> defined the four allelic forms of *FMR1* with respect to CGG repeat size. They stated that consensus has been reached, both in the literature and in the workshops regarding the size of the premutation at 55–200 repeats, and the full mutation at >200 repeats and these ranges agree with those in the Technical Standards and Guidelines as summarized in Table 1. Wittenberger et al. also stated that consensus has not yet been reached for the lower limit of the intermediate or gray zone (i.e., 45–54 repeats or 40–54 repeats).

The clinical significance of intermediate and low premutation size alleles is 3-fold. First, it is the extent to which they may be prone to instability, particularly expansion, in future generations. At the present time, the smallest repeat known to expand to a full mutation in one generation is 59 CGGs.<sup>6,7</sup> Recognizing this and the fact that there is variation between

laboratories and between laboratory methods when determining the exact CGG repeat number, the Laboratory Technical Standards and Guidelines place the boundaries of the premutation range at 55 and 200 CGG repeats. Quality Assurance challenges through the College of American Pathologists have shown that repeat lengths sized using polymerase chain reaction–based techniques can vary by  $\pm 3$ –4 repeats. The Technical Standards and Guidelines allowed for this variation in choosing 55 repeats as the lower limit of the premutation range to avoid missing any women at risk for having a child with the Fragile X syndrome.

Second, the clinical significance is the extent to which these repeat size alleles increase the risk for premutation-associated Fragile X tremor ataxia syndrome (FXTAS). FXTAS is a late-onset neurodegenerative disorder with predominant features of cerebellar ataxia and intention tremor. Onset is usually in persons older than 50 years. The risk and/or severity of the disorder is associated with repeat size, the highest risk being associated with larger repeats. Among individuals with late-onset cerebellar ataxia, the prevalence of premutation alleles was 13 times greater than expected based on its prevalence in the general population as assessed by a recent meta-analysis.<sup>8</sup>

Lastly, the clinical significance of intermediate/low premutation repeat size alleles is the extent to which they impose a risk for premutation-associated ovarian insufficiency. The prevalence of premature ovarian failure (POF) or cessation of menses before 40 years of age is about 20%, although it is highly associated with repeat size: the risk seems to increase with increasing premutation repeat size between 59 and 99, thereafter the risk of POF plateaus or even decreases for women with repeat sizes over 100.<sup>9</sup> Premutation carriers have been identified in about 3% of women with sporadic POF and in about 12% of women with familial POF.<sup>10</sup>

Thus, at this point, the risk and/or severity of all three disorders associated with premutation alleles (i.e., instability during transmission, FXTAS and POF) is established for alleles 55–200 repeats. The risk among the alleles in the lower part of this range, 55–70 is significantly lower than that in the upper range, 70–200, for all three disorders.

Table 2 shows the distribution of repeats among the allelic forms of *FMR1* between 41 repeats and 200 repeats as defined in the two conflicting ACMG publications. The table demonstrates that, were genetic counseling to be based on the Practice

**Table 1**

Comparison of the CGG repeat length ranges for each allelic class as defined by the four reports

Interpretation	Technical standards <sup>2</sup>	Practice guidelines <sup>3</sup>	ACOG committee opinion <sup>4</sup>	Wittenberger et al. <sup>5</sup>
Unaffected	<45	<41	<41	<45
Intermediate, gray zone	45–54	41–60	41–60	45–54
Premutation	55–200	61–200	61–200	55–200
Full mutation	>200	>200	>200	>200

**Table 2**

Comparison of the clinical interpretation of each allelic class by the two sets of guidelines

No. repeats	Interpretation according to technical standards and guidelines	Interpretation according to practice guidelines
41–44	Unaffected	Intermediate, grayzone
45–54	Intermediate, grayzone	Intermediate, grayzone
55–60	Premutation	Intermediate, grayzone
61–200	Premutation	Premutation

Guidelines, individuals with 59 and 60 repeats, who are at risk to have an affected child in the next generation, would not be counseled appropriately. Furthermore, a greater number of patients would be identified to have intermediate or gray zone alleles. As stated above, carrying the label of intermediate or gray zone currently has no established clinical significance and may cause unwarranted concern to families.

In conclusion, the Quality Assurance Committee and the Professional Practice and Guidelines Committee of the ACMG have determined that no changes are required to the ranges published originally in 2001<sup>1</sup> and restated in 2005 in the Technical Standards and Guidelines for Fragile X testing.<sup>2</sup> The ACMG Quality Assurance Committee and the Professional Practice and Guidelines Committee recommend that the following ranges for CGG repeat size be used in the laboratory as well as in clinical practice:

Unaffected: <45  
Intermediate: 45–54  
Premutation: 55–200  
Full mutation: >200

**Kathryn E. Kronquist, PhD, FACMG**

*Molecular/Genetics Department  
Kaiser Permanente Regional Reference Laboratory  
Denver, Colorado*

**Stephanie L. Sherman, PhD, FACMG**

*Department of Human Genetics  
Emory University  
Atlanta, Georgia*

**Elaine B. Spector, PhD, FACMG**  
*UC Denver DNA Diagnostic Laboratory  
University of Colorado Denver  
School of Medicine  
Aurora, Colorado*

## References

- Maddalena A, Richards CS, McGinniss MJ, et al. Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee. *Genet Med* 2001;3:200–205.
- Spector EB, Kronquist KE. Fragile X: technical standards and guidelines. ACMG standards and guidelines for clinical genetics laboratories, 2005. Available at: [www.acmg.net](http://www.acmg.net).
- Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. *Genet Med* 2005;7:584–587.
- ACOG committee opinion No. 338: Screening for Fragile X syndrome. *Obstet Gynecol* 2006;107:1483–1485.
- Wittenberger MD, Hagerman RJ, Sherman SL, et al. The FMR1 premutation and reproduction. *Fertil Steril* 2007;87:456–465.
- Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. *Am J Hum Genet* 2004;74:805–816.
- Nolin SL, Brown WT, Glicksman A, et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. *Am J Hum Genet* 2003;72:454–464.
- Jacquemont S, Leehey MA, Hagerman RJ, et al. Size bias of fragile X premutation alleles in late-onset movement disorders. *J Med Genet* 2006;43:804–809.
- Ennis S, Ward D, Murray A. Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers. *Eur J Hum Genet* 2006;14:253–255.
- Sherman SL, Taylor K, Allen EG. FMR1 premutation: a leading cause of inherited ovarian dysfunction. In: Arrieta I, Penagarikano O, et al., editors. Fragile sites: new discoveries and changing perspectives. Hauppauge: Nova Science Publishers, Inc., 2007:229–320.